Solasia Pharma K.K.
4597
Rank in Stocks
#23474
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is... Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
Share Price
$0.15191172
Last synced: 2026-11-10
Market Cap
$41.47M
Change (1 day)
4.35%
Change (1 year)
-26.63%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Solasia Pharma K.K. (4597)
Category
Healthcare
Operating Margin for Solasia Pharma K.K. (4597)
Operating Margin as of November 2026 TTM: -229.90%
According to Solasia Pharma K.K.'s latest financial reports, its current operating margin (TTM) is -229.90%. At the end of 2025 the company had an operating margin of -200.23%.
Operating Margin history for Solasia Pharma K.K. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -229.90% | 14.82% |
| 2025 | -200.23% | -36.15% |
| 2024 | -313.61% | 69.89% |
| 2023 | -184.60% | -18.42% |
| 2022 | -226.28% | -47.71% |
| 2021 | -432.74% | -40.74% |
| 2020 | -730.18% | 442.88% |
| 2019 | -134.50% | -82.33% |
| 2018 | -761.01% | 209.67% |
| 2017 | -245.75% | 166.40% |
| 2016 | -92.25% | -69.86% |
| 2015 | -306.11% | -94.79% |
| 2014 | -5,873.59% | 0.00% |
| 2013 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -100.08% |
DE
|
|
| 19.68% | -100.09% |
DE
|
|
| 13.26% | -100.06% |
JP
|
|
| 17.08% | -100.07% |
CH
|
|
| 14.92% | -100.06% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Solasia Pharma K.K.'s operating margin
What is Solasia Pharma K.K.'s operating margin?
Solasia Pharma K.K.'s operating margin is -229.90%, as of Nov 2026.
What was Solasia Pharma K.K.'s operating margin in 2025?
In 2025, Solasia Pharma K.K.'s operating margin was -200.23%, compared with -313.61% in 2024.
How has Solasia Pharma K.K.'s operating margin changed since 2020?
From 2020 to 2025, Solasia Pharma K.K.'s operating margin was highest in 2023 (-184.60%) and lowest in 2020 (-730.18%).
How does Solasia Pharma K.K.'s operating margin compare with similar companies?
Solasia Pharma K.K.'s operating margin (-229.90%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.